tradingkey.logo

Amarin Corporation PLC

AMRN
15.710USD
+0.040+0.26%
終値 11/07, 16:00ET15分遅れの株価
326.74M時価総額
損失額直近12ヶ月PER

Amarin Corporation PLC

15.710
+0.040+0.26%

詳細情報 Amarin Corporation PLC 企業名

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Amarin Corporation PLCの企業情報

企業コードAMRN
会社名Amarin Corporation PLC
上場日Apr 01, 1993
最高経営責任者「CEO」Mr. Aaron D. Berg
従業員数275
証券種類Depository Receipt
決算期末Apr 01
本社所在地WeWork One Central Plaza Dame Street
都市DUBLIN
証券取引所NASDAQ Capital Market Consolidated
Ireland
郵便番号D02 K7K5
電話番号35316699020
ウェブサイトhttps://amarincorp.com/
企業コードAMRN
上場日Apr 01, 1993
最高経営責任者「CEO」Mr. Aaron D. Berg

Amarin Corporation PLCの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.95K
--
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter Fishman
Mr. Peter Fishman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Keith L. Horn
Mr. Keith L. Horn
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.95K
--
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--

収益内訳

データなし
データなし
事業別
地域別
データなし

株主

更新時刻: Sun, Oct 26
更新時刻: Sun, Oct 26
株主統計
種類
株主統計
株主統計
比率
Sarissa Capital Management, L.P.
5.98%
Kynam Capital Management LP
2.77%
Acadian Asset Management LLC
1.16%
Eversept Partners, LP
0.80%
Morgan Stanley & Co. LLC
0.71%
他の
88.58%
株主統計
株主統計
比率
Sarissa Capital Management, L.P.
5.98%
Kynam Capital Management LP
2.77%
Acadian Asset Management LLC
1.16%
Eversept Partners, LP
0.80%
Morgan Stanley & Co. LLC
0.71%
他の
88.58%
種類
株主統計
比率
Hedge Fund
11.40%
Investment Advisor
2.98%
Investment Advisor/Hedge Fund
1.81%
Research Firm
1.32%
Individual Investor
0.99%
Family Office
0.24%
Foundation
0.18%
Pension Fund
0.09%
他の
81.00%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
311
3.72M
17.89%
-1.05M
2025Q2
337
3.85M
18.61%
-1.56M
2025Q1
349
5.67M
20.22%
+144.25K
2024Q4
362
81.89M
19.91%
-21.31M
2024Q3
365
76.69M
18.66%
-50.88M
2024Q2
389
87.45M
21.29%
-59.57M
2024Q1
405
98.68M
24.03%
-57.40M
2023Q4
423
103.82M
25.42%
-56.37M
2023Q3
447
95.61M
23.44%
-78.96M
2023Q2
464
107.90M
26.46%
-89.05M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Sarissa Capital Management, L.P.
1.24M
6.01%
-4.00
-0.00%
Jun 30, 2025
Kynam Capital Management LP
576.11K
2.79%
-44.62K
-7.19%
Jun 30, 2025
Acadian Asset Management LLC
241.05K
1.17%
+51.47K
+27.15%
Jun 30, 2025
Eversept Partners, LP
167.28K
0.81%
-2.68K
-1.58%
Jun 30, 2025
Morgan Stanley & Co. LLC
147.27K
0.71%
+31.23K
+26.91%
Jun 30, 2025
SCP Investment, LP
125.00K
0.6%
--
--
Jun 30, 2025
Longitude (Cayman) Ltd
81.00K
0.39%
-37.50K
-31.65%
Dec 31, 2024
Berg (Aaron D.)
80.71K
0.39%
+36.64K
+83.12%
Jun 26, 2025
WaterFront Wealth, Inc.
94.73K
0.46%
-31.00K
-24.66%
Jun 30, 2025
Two Sigma Investments, LP
76.39K
0.37%
-86.45K
-53.09%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
SPDR S&P International Small Cap ETF
0.02%
Global X Aging Population ETF
0%
ActivePassive International Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Invesco Nasdaq Biotechnology ETF
比率0.03%
ProShares Ultra Nasdaq Biotechnology
比率0.03%
SPDR S&P International Small Cap ETF
比率0.02%
Global X Aging Population ETF
比率0%
ActivePassive International Equity ETF
比率0%
Invesco NASDAQ Future Gen 200 ETF
比率0%
SPDR Portfolio Developed World ex-US ETF
比率0%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
Mar 12, 2025
Merger
20→1
日付
種類
比率
Mar 12, 2025
Merger
20→1
KeyAI